title: Current choice of treatments for neovascular AMD.
abstract: Age-related macular degeneration is the leading cause of irreversible blindness in developed countries with the neovascular form accounting for the majority of severe vision loss in the disease. The management of wet age-related macular degeneration has improved drastically in the past decade as anti-VEGF agents took its place at the forefront of treatment. As the choice of therapy is based on a number of factors, this review summarizes the pivotal studies that brought these agents to use and compares the different agents currently available. This review also briefly describes the promising new therapies that are in development.
authors.affiliation: Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA.
authors.forename: Kevin
authors.initials: K
authors.lastname: Lai
authors.forename: Gennady
authors.initials: G
authors.lastname: Landa
mesh_terms: D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D004364:Pharmaceutical Preparations; D042461:Vascular Endothelial Growth Factor A
keywords: Avastin; Eylea; Lucentis; neovascular age-related macular degeneration; treatment